Dexcom Company Analysis.pdf

A Progressive Digital Media business

COMPANY PROFILE

DexCom Inc

REFERENCE CODE: BD2E5033-961C-48ED-A0B0-3EAED86A0FE5 PUBLICATION DATE: 01 Sep 2018 www.marketline.com COPYRIGHT MARKETLINE. THIS CONTENT IS A LICENSED PRODUCT AND IS NOT TO BE PHOTOCOPIED OR DISTRIBUTED

DexCom Inc TABLE OF CONTENTS

TABLE OF CONTENTS Company Overview ........................................................................................................3 Key Facts ......................................................................................................................... 3 Tickers ............................................................................................................................. 4 Business Description .....................................................................................................5 Corporate Strategy .........................................................................................................7 Business Segment..........................................................................................................8 History ............................................................................................................................. 9 Key Employees .............................................................................................................15 Key Employee Biographies .........................................................................................16 Major Products & Services ..........................................................................................17 SWOT Analysis .............................................................................................................18 Top Competitors ...........................................................................................................22 Company View ..............................................................................................................23 Locations And Subsidaries .........................................................................................26 Financial Overview .......................................................................................................27

DexCom Inc © MarketLine

Page 2

DexCom Inc Company Overview

Company Overview

COMPANY OVERVIEW DexCom Inc (DexCom) is a medical device company that performs design, development and commercialization of continuous glucose monitoring systems for ambulatory and in-hospital use. The company’s major products include DexCom G4, DexCom G4 Platinum and other continuous glucose monitoring systems. DexCom’s in-hospital product, GlucoClear, is a blood-based in-vivo automated glucose monitoring system. It also provides training and support services. DexCom offer its products to endocrinologists, physicians, diabetes educators and others. The company distributes its products in the US, Canada, Australia, New Zealand, Europe, Asia, Latin America and the Middle East through direct sales force and a network of distributors. DexCom is headquartered in San Diego, California, the US. The company reported revenues of (US Dollars) US$718.5 million for the fiscal year ended December 2017 (FY2017), an increase of 25.3% over FY2016. The operating loss of the company was US$42.5 million in FY2017, compared to an operating loss of US$63.9 million in FY2016. The net loss of the company was US$50.2 million in FY2017, compared to a net loss of US$65.6 million in FY2016. The company reported revenues of US$266.7 million for the third quarter ended September 2018, an increase of 10% over the previous quarter. Key Facts

KEY FACTS Head Office

DexCom Inc 6340 Sequence Drive San Diego California San Diego California USA

Phone

1 858 2000200

Fax

1 302 6365454

Web Address

www.dexcom.com

Revenue / turnover (USD Mn)

718.5

Financial Year End

December

Employees

2,290

NASDAQ Ticker

DXCM

DexCom Inc © MarketLine

Page 3

DexCom Inc Company Overview

Tickers

TICKERS DXCM

DexCom Inc © MarketLine

Page 4

DexCom Inc Company Overview

Business Description

BUSINESS DESCRIPTION DexCom Inc (DexCom) is a provider of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and healthcare providers in the hospital for the treatment of diabetic and nondiabetic patients. The company offers two product lines, namely, Ambulatory product line and In-Hospital product line. DexCom’s Ambulatory product line includes Seven Plus, DexCom G4, DexCom G4 Platinum, DexCom Share System and DexCom G5 Mobile. The Seven Plus CGM system is a short-term continuous glucose monitoring system (STS) device designed for seven days of continuous uninterrupted use. The devices help in measuring the glucose levels, and provide up to 288 glucose measurements a day and incorporate additional user interface and algorithm enhancements that are intended to make its glucose monitoring function accurate and customizable. DexCom’s G4 Platinum provides continuous glucose monitoring with wireless reporting every five minutes. It tracks glucose levels continuously for seven days throughout the 24-hour period using wireless technology. It enables users to view their glucose levels on demand. The system allows diabetics to program personalized information, such as glucose targets and alerts. The system has an alarm feature to alert the user if glucose levels rise or fall to dangerous levels. DexCom G4 Platinum (Pediatric) is the only CGM system approved for kids aged two years and above. DexCom also offers G4 Platinum Receiver with Share that has built in bluetooth wireless communication. It enables remote viewing and sharing of glucose levels, trends and data between the person with diabetes and its family members and friends. DexCom mobile application is also available on iOS and Android platform. DexCom’s CGM system consists of three parts, which comprise a sensor, a transmitter and a receiver. The sensor is flexible and tiny, which easily fits into the insertion needle completely. The product is also provided with a detachable and disposable applicator. The transmitter is water resistant and small in nature. It transmits glucose signals wirelessly. It also provides in sensor data processing. The receiver supports an easy viewing glucose trends in different colors. The company’s in-hospital product GlucoClear is a blood-based in-vivo automated glucose monitoring system developed in collaboration with Edwards Lifesciences. DexCom entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market. The company received CE Mark approval for GlucoClear glucose monitoring system. The company also develops DexCom SHARE remote monitoring system. Through secure wireless connections, DexCom SHARE notifies another person of a user's G4 Platinum sensor glucose information when the G4 Platinum Receiver is docked in the DexCom SHARE Cradle. It provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Apart from these products, the company also offers data transfer service through its subsidiary, SweetSpot Diabetes Care, Inc. It is a health data company with focus on improving the use of data in the

DexCom Inc © MarketLine

Page 5

DexCom Inc Company Overview

treatment of diabetes. It specializes in turning raw output from patient devices into reports that are useful for researchers, health care providers, and patients. SweetSpot’s software provides an advanced cloudbased platform for healthcare providers, individuals and researchers. The company’s research and development activities are focused on the commercialization of its ambulatory continuous glucose monitoring systems. In FY2017, the company spent US$185.4 million on its research and development activities, which as a percentage of revenue stood at 25.8%. DexCom conducts its sales and marketing operations through direct sales personnel and distributors. The company has a manufacturing facility in San Diego, California.

DexCom Inc © MarketLine

Page 6

DexCom Inc Company Overview

Corporate Strategy

CORPORATE STRATEGY DexCom seeks to become a leading provider of continuous glucose monitoring systems and related products through the development of innovative products that integrate the continuous glucose monitoring technologies into insulin pump delivery systems of the respective partners. In addition, the company develops products through internal development, strong partner relationships and strategic alliances. The key steps in achieving its objective include Establishing and maintaining its technology platform as the leading approach to continuous glucose monitoring and leverage its development expertise to rapidly bring products to market, including for expanded indications. Driving the adoption of its ambulatory products through a direct sales and marketing effort, as well as key distribution arrangements. Driving additional adoption through technology integration partnerships such as its current partnerships with Eli Lilly, Insulet, Tandem and others. Seeking broad coverage policies and reimbursement for its products from private third-party payors and national health systems such as Medicare. Driving increased utilization and adoption of its products through a cloud-based data repository platform that enables people with diabetes to aggregate and analyze data from numerous diabetes devices and share the data with their healthcare providers. Expanding the use of its products to other patient care settings and patient demographics, including people with Type 2 diabetes. Providing a high level of customer support, service and education. Pursuing the highest safety and quality levels for its products.

DexCom Inc © MarketLine

Page 7

DexCom Inc Company Overview

Business Segment

BUSINESS SEGMENT Geography The US Performance Reported revenue of US$596.2 million for FY2017, which grew 19.8% YoY, and recorded CAGR of 31.0% during 2015-17. The US accounted for 83.0% of the company's revenue in FY2017.

Outside of the US Performance Reported revenue of US$122.3 million for FY2017, which grew 61.3% YoY, and recorded CAGR of 49.7% during 2015-17. Outside of the US accounted for 17.0% of the company's revenue in FY2017.

DexCom Inc © MarketLine

Page 8

DexCom Inc Company Overview

History

HISTORY Contracts/Agreements Year: 2018 In January, the company entered into an agreement with UnitedHealthcare to perform individualized glucose management pilot program using UnitedHealthcare's novel digital wearable technology to enable people with type 2 diabetes to better manage their condition.

Acquisitions/Mergers/Takeovers Year: 2018 In August, the company acquired TypeZero Technologies, Inc.

Contracts/Agreements Year: 2017 In November, the company signed a development agreement with Eli Lilly and Co (Lilly) to include Dexcom CGM into Lilly's connected diabetes ecosystem. According to the terms of the agreement, the companies will combine Lilly's smart insulin delivery devices with Dexcom CGM to enhance diabetes management.

Contracts/Agreements Year: 2017 In September, DexCom entered into collaboration with Fitbit to develop and market products to help people better manage their diabetes and get a comprehensive picture of their overall health with mobile tools.

Corporate Changes/Expansions Year: 2016 In June, Dexcom plan to open up a new state of the art manufacturing facility in Arizona for its glucose monitoring business.

Commercial Operation Year: 2016

DexCom Inc © MarketLine

Page 9

DexCom Inc Company Overview

In June, Dexcom's researchers informed CGM technology improvement towards accuracy and reliability, to use CGM as their primary source for glucose information for Type 1 Diabetes.

Plans/Strategy Year: 2016 In June, Dexcom planned a new manufacturing facility with latest technologies in Greater Phoenix, Arizona for its continuous glucose monitoring business.

Corporate Changes/Expansions Year: 2016 In November, Dexcom set up a new HQ in Edinburgh.

Corporate Changes/Expansions Year: 2016 In November, Dexcom opened a new headquarters in Scotland.

Regulatory Approval Year: 2015 In January, the company's G4 PLATINUM Continuous Glucose Monitoring System with Share has received U.S. Food and Drug Administration approval .

Contracts/Agreements Year: 2015 In June, Glooko Inc. entered into an agreement with Dexcom, Inc.and Insulet Corporation to unify all diabetes relevant device data into a single, unified platform to enable both patients and healthcare providers to improve health outcomes.

Contracts/Agreements Year: 2015 In July, Tandem Diabetes Care, Inc. entered into non-exclusive Development Agreement with Dexcom, Inc. for integration of future generation Tandem insulin pumps with the Dexcom G5 and G6 continuous glucose monitoring systems.

DexCom Inc © MarketLine

Page 10

DexCom Inc Company Overview

Contracts/Agreements Year: 2015 In August, DexCom entered into an agreement with the life sciences team at Google for jointly development of a series of next-generation CGM products.

Regulatory Approval Year: 2015 In August, the company received the U.S. Food and Drug Administration (FDA) approval for the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System.

Contracts/Agreements Year: 2015 In September, the company and Edwards Lifesciences Corp entered into agreement to develop continuous glucose monitoring technology for use in hospitals.

Corporate Awards Year: 2014 In April, the company has been awarded as the most innovative company within the healthcare industry by Fast Company.

Regulatory Approval Year: 2014 In February, the company received the US FDA approval for its CGM device: DexCom G4 Platinum (Pediatric) for use in children aged 2 to 17 years with diabetes.

Regulatory Approval Year: 2014 In June, the company received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4 PLATINUM Professional CGM.

Contracts/Agreements

DexCom Inc © MarketLine

Page 11

DexCom Inc Company Overview

Year: 2014 In August, the company entered into an agreement with Insulet to develop a CGM-Integrated Personal Diabetes Manager.

Plans/Strategy Year: 2014 In August, Dexcom and Asante Solutions planned to enable the Dexcom mobile app platform, which is currently under development, to integrate and display insulin data from the Asante Snap Insulin Pump.

Regulatory Approval Year: 2013 In February, the company received CE Mark approval for DexCom G4 Platinum (Pediatric).

Research and Development Year: 2013 The company submitted a PMA supplement to the US FDA seeking approval for the new DexCom SHARE remote monitoring system.

Contracts/Agreements Year: 2013 In January, Tandem Diabetes Care announced development and commercialization agreement with Dexcom, Inc. to include Dexcom's newest continuous glucose monitoring system, the G4 PLATINUM.

Regulatory Approval Year: 2012 In July, the company received CE Mark approval for DexCom G4 system.

Contracts/Agreements Year: 2012 The company signed a joint product development agreement with Tandem Diabetes Care, Inc.

Regulatory Approval

DexCom Inc © MarketLine

Page 12

DexCom Inc Company Overview

Year: 2012 In October, the company received the US FDA approval for DexCom G4 Platinum.

Acquisitions/Mergers/Takeovers Year: 2012 In February, the company acquired SweetSpot Diabetes Care, Inc., a healthcare-focused information technology company.

Others Year: 2010 In June, the company received a warning letter from the US FDA. which cites a deviation related to MDR reporting for complaints involving sensor wire fractures underneath a patient's skin and recommends some specific changes to the company's warning and precaution statements in its product labeling.

Contracts/Agreements Year: 2009 In May, the company entered into an agreement with Edwards Lifesciences Corporation to jointly develop and market GlucoClear, an in-hospital automatic blood glucose monitoring system.

Regulatory Approval Year: 2009 In October, the company received CE Mark approval for Seven Plus continuous glucose monitoring system.

Contracts/Agreements Year: 2008 The company entered into a distribution agreements with RGH Enterprises, Inc., for selling its durable systems and disposable units.

Contracts/Agreements Year: 2008

DexCom Inc © MarketLine

Page 13

DexCom Inc Company Overview

In November, The company entered into an agreement with Edwards Lifesciences Corporations to develop products for continuously monitoring blood glucose levels in patients hospitalized for a variety of conditions.

Regulatory Approval Year: 2008 In December, the company received CE Mark approval for Seven CGM system.

Contracts/Agreements Year: 2008 The company signed a joint development agreement with Animas Corporation and Insulet Corporation.

Contracts/Agreements Year: 2008 In January, the company entered into a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring (CGM) technology into Animas insulin pumps.

New Product Approvals Year: 2006 Dexcom received the US FDA approval for STS continuous glucose monitoring system and DM consumer data manager.

Incorporation/Establishment Year: 1999 DexCom, Inc. was founded.

DexCom Inc © MarketLine

Page 14

DexCom Inc Company Overview

Key Employees

KEY EMPLOYEES Name

Job Title

Board

Kevin Sayer

Chairman, Chief Executive Officer, Director, President

Executive Board

Rick Doubleday

Executive Vice President, Chief Commercial Officer

Senior Management

Patrick Murphy

Chief Compliance Officer, General Counsel

Senior Management

Quentin Blackford

Chief Financial Officer

Senior Management

Eric Topol, M.D.

Director

Non Executive Board

Barbara E. Kahn

Director

Non Executive Board

Jay S. Skyler, M.D.

Director

Non Executive Board

Steven R. Altman

Director

Non Executive Board

Mark G. Foletta

Director

Non Executive Board

Nick Augustinos

Director

Non Executive Board

Richard Collins

Director

Non Executive Board

Andrew K. Balo

Executive Vice President-Clinical, Regulatory and Quality

Senior Management

Steven R. Pacelli

Executive Vice President-Corporate Development

Senior Management

Don Abbey

Executive Vice President-Quality & Information Technology

Senior Management

Jacob Leach

General Manager-Europe, Middle East Senior Management & Africa

Annika Jimenez

Senior Vice President-Data

Senior Management

Claudia Graham

Senior Vice President-Global Access

Senior Management

Heather Ace

Senior Vice President-Human Resources

Senior Management

Jeffrey C. Moy

Senior Vice President-Operations

Senior Management

DexCom Inc © MarketLine

Page 15

DexCom Inc Company Overview

Key Employee Biographies

KEY EMPLOYEE BIOGRAPHIES Kevin Sayer Board:Executive Board Job Title:Chairman, Chief Executive Officer, Director, President Since:2015 Age:60 Mr. Kevin Sayer has been the Chairman since 2018 and served as President, Chief Executive Officer, Director of DexCom since January 2015. Previously, Mr. Sayer has served as the President and the Chief Operating Officer of the company. Between 2007 and 2010, he served as the Chief Financial Officer of Biosensors International Group, Ltd. Prior to joining Biosensors, Mr. Sayer served as an independent healthcare and medical technology industry consultant from 2005 to 2007.

Rick Doubleday Board:Senior Management Job Title:Executive Vice President, Chief Commercial Officer Since:2015 Age:55 Rick Doubleday has been the Executive Vice President, Chief Commercial Officer of the company since January 2015. Prior to this, he served as Vice President of Sales of the company from June 2009. Before joining Dexcom, he worked with Johnson & Johnson.

DexCom Inc © MarketLine

Page 16

DexCom Inc Company Overview

Major Products & Services

MAJOR PRODUCTS & SERVICES DexCom is a US-based company that carries out the design, development and commercialization of continuous glucose monitoring systems for ambulatory and in-hospital use. The major products and services of the company includes: Products: Ambulatory Product Line: SEVEN PLUS DexCom G4 DexCom G4 PLATINUM DexCom Share System DexCom G5 Mobile In-Hospital Product: GlucoClear In-Vivo Automated Glucose Monitoring System Services:

Support Training Brands: SEVEN DexCom GlucoClear SHARE

DexCom Inc © MarketLine

Page 17

DexCom Inc Company Overview

SWOT Analysis

SWOT ANALYSIS DexCom Inc (DexCom) develops and markets continuous glucose monitoring systems for use by persons with diabetes. An extensive sales network and strong research and development focus are its major strengths even as history of operating loss is a major cause of concern for the company. Although stiff competition, dependence on distributors and patent expiry could negatively affect its growth prospects, DexCom could benefit from the strategic collaborations and growing diabetic care market. Strength

Weakness

Proprietary Technology Agreements and Collaborations Research and Development Focus

History of Operating Losses

Opportunity

Threat

Strategic Agreements Growing Diabetes Care Devices Market

Government Regulations Stiff Competition Uncertain R&D Outcomes

Strength Proprietary Technology Proprietary technologies provide a competitive advantage to the company. Harnessing its proprietary technologies including sensor technology, receiver and transmitter technology, algorithms, software, implant tools and sealed protective housings, DexCom develops innovative solutions for continues glucose monitoring. The company’s sensors include biomaterials, electrochemistry, membrane systems and low power microelectronics. Its membrane technology consists of multiple polymer layers which are configured to selectively allow the mix of glucose and oxygen through the membrane, react with a glucose specific enzyme to create low level electrical signal, measured in pico-amperes. The company use radiofrequency telemetry to wirelessly transmit information from sensor to receiver, which processes and displays real-time and trended glucose values. Proprietary algorithms and software are programmed into the receiver to process glucose data and display it on a user-friendly graphical user interface. Agreements and Collaborations The company entered into certain partnerships and agreements that are aimed at enhancing its business operations and existing product line. This could help the company maintain its competitive position in the industry. The company entered into a definitive collaboration agreement with Edwards Lifesciences Corporation, to develop products for continuously monitoring blood glucose levels. Through this agreement, the company developed continuous glucose sensing technology for critically ill diabetic and non-diabetic patients. The company entered into an agreement with Tandem Diabetes Care, Inc., to

DexCom Inc © MarketLine

Page 18

DexCom Inc Company Overview

integrate continuous glucose monitoring technology into the insulin pump product offering of Tandem. Through this agreement, the company integrates best-in-class diabetes care to patients. Research and Development Focus Its R&D activities focus on improving existing products and developing new products for ambulatory use by people with diabetes and healthcare providers in the hospital for the treatment of diabetic and nondiabetic patients. Its research and development expenses consisting of engineering and research expenses related to its continuous glucose monitoring technology, clinical trials, regulatory expenses, quality assurance programs, materials and products for clinical trials increased from US$156.1 million in FY2016 to US$185.4 million in FY2017. The company’s expertise in R&D enabled it to obtain various patents in core membrane and sensor technologies. As of January 2018, the company held 391 issued US patents, 42 granted European patents, and 231 additional US patent applications pending, 56 European patent applications pending, and 21 other international applications.

Weakness History of Operating Losses The company carries a history of significant and continued operating losses, which is a serious cause for concern to the company's growth. DexCom's growing deficit and operating loss are serious causes for concern as the company could face problems in financing its research projects and will also feel the pressure of meeting its operational requirements. The company reported operating loss of US$42.5 million in FY2017, and net loss of US$50.2 million in FY2017. This was mainly due to increase in operating expenses from US$442.3 million in FY2016 to US$534.6 million in FY2017. As of December 31, 2017, the company's accumulated deficit was US$671.8 million.

Opportunity Strategic Agreements The company entered into strategic agreements for enhancing its business operations and existing product line. In January 2018, DexCom entered into an agreement with UnitedHealthcare to perform individualized glucose management pilot program using UnitedHealthcare's novel digital wearable technology to help people with Type 2 diabetes manage their condition in real time. In November 2017, the company signed a development agreement with Eli Lilly and Co (Lilly) to include Dexcom CGM into Lilly's connected diabetes ecosystem. According to the terms of the agreement, the companies will combine Lilly's smart insulin delivery devices with Dexcom CGM to enhance diabetes management. In September 2017, DexCom entered into collaboration with Fitbit to develop and market products to help people better manage their diabetes and get a comprehensive picture of their overall health with mobile tools. Growing Diabetes Care Devices Market

DexCom Inc © MarketLine

Page 19

DexCom Inc Company Overview

Food habits, obesity, lifestyle changes and hypertension are contributing to the growing incidence of diabetes. Growing awareness about diabetes is leading to improvement in its diagnosis and a consequent increase in the number of diabetics taking medications. The self-monitoring of blood glucose has become an integral part of diabetes management. Self-monitoring is done using blood glucose meters, test strips and lancing devices. Patients can be easily trained to use these devices to check their blood glucose levels. An estimated 382 million patients are diagnosed with diabetes worldwide and the number is expected to grow to 592 million by 2035. The annual cost of treatment of diabetes and its complications were expected to rise to US$560 billion by FY2030. The global glucose monitoring market is expected to reach US$14,306.4 million by FY2020, according to in-house forecasts. The global glucose monitoring market is driven by major categories including Blood Glucose Meters, Blood Glucose Test Strips and Lancets. Blood Glucose Test Strips are the major category in the glucose monitoring market. The global market for Blood Glucose Test Strips is forecast to reach US$12,618.1 million by FY2020. This category is expected to generate revenue of US$2,847.1 million by FY2020 in Asia Pacific; US$3,249 million in Europe; and US$5,881.5 million in North America. The global blood glucose meters market is expected to reach US$ 1,186.1 million by FY2020 and the global lancets market is expected to reach US$502.2 million by FY2020. The market is expected to register growth with the increasing diabetic population, the availability of reimbursement for diabetes care devices and blood glucose test strips. Targeted marketing programs would ensure that the company continues to improve its market share in the global diabetes care devices market.

Threat Government Regulations The medical device markets are highly competitive and evolving, which could be a cause for concern to the company. With the entry of many new players in this market, competition is expected to intensify in the near future, which could result in price reductions. The company operates in a highly regulated industry, where a variety of statutes and regulations are in place for the testing, manufacture and sale of diagnostic products. The company has to obtain regulatory approvals before commercializing the products. Failure to comply with the present or future regulations related to clinical, laboratory and manufacturing practices may result in delayed approval of the device, product recalls, and cancellation of permission to produce or sell the device. Increased regulation of the diagnostic market could increase the company’s costs by increasing the time and cost of bringing new devices to market. The company’s financial position could also be adversely affected by its inability to obtain or retain regulatory approvals on a timely basis, as this will delay the commercialization of its products. Stiff Competition The company faces intense competition in the market for diabetic care devices. Its performance could be affected by the competitive environment in the medical equipment sector and customer preferences. The company’s competitors will continue to enhance their products or develop new products. Technological

DexCom Inc © MarketLine

Page 20

DexCom Inc Company Overview

advances by any player in the market could render its present or future products obsolete or uneconomical. The demand for its products depends on the competitive atmosphere, including the timely development and introduction of new and competitive products and the company’s response to downward pricing to sustain competition. Factors including changes in customer order patterns, changing development programs or competitors’ new products could impact the company’s competitive ability. The company might not achieve future growth projections, if it fails to successfully compete with its competitors or develop new technologies. Uncertain R&D Outcomes Adverse or inconclusive results from preclinical testing or clinical trials may substantially delay or halt the development of the company's various product candidates, consequently affecting its timeliness for profitability. The outcome of clinical trials is always a subject of uncertainty. After the discovery of a new compound, substantial amount of money and a great deal of time need to be invested to successfully launch a new product. Moreover, it may become necessary to discontinue clinical development if the effectiveness of a drug is not proven as initially expected, or if serious adverse effects arise. In addition, medical devices are subject to legal restrictions in every country and authorization from regulatory authorities is a prerequisite for a product launch in every country. It is difficult to accurately foresee when approvals for a new product could be obtained.

DexCom Inc © MarketLine

Page 21

DexCom Inc Company Overview

Top Competitors

TOP COMPETITORS The following companies are the major competitors of DexCom Inc Abbott Diabetes Care Inc Abbott Laboratories Bayer Corp Becton Dickinson and Co LifeScan Inc MediSense Inc. Medtronic Plc

DexCom Inc © MarketLine

Page 22

DexCom Inc Company Overview

Company View

COMPANY VIEW A part of the Management’s Discussion and Analysis of DexCom Inc is given below. It has been taken from the company’s 10-K filing 2017. Overview We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers for the treatment of people with diabetes. Unless the context requires otherwise, the terms we, us, our, the company, or DexCom refer to DexCom Inc and its subsidiaries. From inception to 2006, we devoted substantially all of our resources to start-up activities, raising capital and research and development, including product design, testing, manufacturing and clinical trials. Since 2006, we have devoted considerable resources to the commercialization of our continuous glucose monitoring systems, including the G4 Platinum and G5 Mobile, as well as the continued research and clinical development of our technology platform. From inception through December 31, 2017, we have generated US$2.4 billion of product and development grant and other (non-product) revenue, and we have incurred net losses in each year since our inception in May 1999. As of December 31, 2017, we had an accumulated deficit of US$671.8 million. We expect our losses to continue as we proceed with our commercialization and research and development activities. We have financed our operations primarily through offerings of equity securities and debt, and the sales of our products. Financial Operations Revenue We sell our durable systems and disposable units through a direct sales force in the United States, Canada and portions of Europe, and through distribution arrangements in the United States, Canada, Australia, New Zealand, and in portions of Europe, Asia, Latin America, the Middle East and Africa. We have contracts with certain distributors, the majority of whom stock our products, and we refer to these distributors as Stocking Distributors, whereby the Stocking Distributors fulfill orders for our product from their inventory. We also have contracts with certain distributors that do not stock our products, but rather products are shipped directly to the customer by us on behalf of our distributor, and we refer to these distributors as Drop-Ship Distributors. We expect that revenues we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality with lower sales in the first quarter of each year, compared to the previous fourth quarter, related to annual insurance deductible resets and unfunded flexible spending accounts. Cost of Sales Cost of sales includes direct labor and materials costs related to each product sold or produced, including assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations. Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality

DexCom Inc © MarketLine

Page 23

DexCom Inc Company Overview

assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based compensation, facility expense, supplies and purchased services. All of our manufacturing costs are included in cost of sales. Research and Development Our research and development expenses primarily consist of engineering and research expenses related to our continuous glucose monitoring technology, clinical trials, regulatory expenses, quality assurance programs, materials and products for clinical trials. Research and development expenses are primarily related to employee compensation, including salary, fringe benefits, share-based compensation, and temporary employee expenses. We also incur significant expenses to operate our clinical trials including clinical site reimbursement, clinical trial product and associated travel expenses. Our research and development expenses also include fees for design services, contractors and development materials. Selling, General and Administrative Our selling, general and administrative expenses primarily consist of salary, fringe benefits and sharebased compensation for our executive, financial, sales, marketing, information technology and administrative functions. Other significant expenses include commissions, marketing and advertising, IT software license costs, insurance, professional fees for our outside legal counsel and independent auditors, litigation expenses, patent application expenses, unoccupied facilities and consulting expenses. Results of Operations Fiscal year ended December 31, 2017 Compared to December 31, 2016. Revenue, Cost of Sales and Gross Profit Revenues increased US$145.2 million to US$718.5 million for the twelve months ended December 31, 2017 compared to US$573.3 million for the twelve months ended December 31, 2016 based primarily on increased sales volume of our disposable sensors due to the continued growth of our installed base of customers using our G4 PLATINUM and G5 Mobile systems and durable systems to both new and existing customers. Revenue attributable to our disposable sensors and durable systems was approximately 70% and 30%, respectively, of total revenue, for each of the twelve months ended December 31, 2017 and 2016. Revenue from products shipped to our distributors, which are primarily Stocking Distributors, for the twelve months ended December 31, 2017 was approximately US$538.0 million or 75% of our revenue compared to US$411.8 million or 72% of our total revenue for the twelve months ended December 31, 2016. Cost of sales increased US$31.5 million to US$226.4 million for the twelve months ended December 31, 2017 compared to US$194.9 million for the twelve months ended December 31, 2016, primarily due to increased sales volume. The gross profit of US$492.1 million, or 68% for the twelve months ended December 31, 2017 increased US$113.7 million compared to US$378.4 million, or 66% for the same period in 2016, primarily due to increased revenue and a decrease in warranty costs primarily related to the February 23, 2016 customer notification regarding the audible alarms and alerts associated with our receivers which was classified as a voluntary Class 1 recall by the FDA and was closed by the FDA as of August 11, 2017. Research and Development. Research and development expense increased US$29.3 million to US$185.4 million for the twelve

DexCom Inc © MarketLine

Page 24

DexCom Inc Company Overview

months ended December 31, 2017, compared to US$156.1 million for the twelve months ended December 31, 2016. The increase was primarily due to US$18.3 million in additional salaries, bonus and payroll related costs, US$8.4 million of additional expensed equipment, and US$2.4 million of additional clinical trial costs related to development of our future products. Selling, General and Administrative. Selling, general and administrative expense increased US$63.0 million to US$349.2 million for the twelve months ended December 31, 2017, compared to US$286.2 million for the twelve months ended December 31, 2016. The increase was primarily due to higher headcount related selling, marketing and customer support costs to support revenue growth and the continued commercialization of our products. Significant elements of the increase in selling, general, and administrative expenses included US$37.8 million in additional salaries, bonus, and payroll related costs, US$10.6 million of additional marketing costs, US$4.4 million of additional software license costs, and US$1.5 million in additional consulting fees. Other Income (Expense). Other income was US$3.4 million for the twelve months ended December 31, 2017 compared to other expense of US$0.7 million for the twelve months ended December 31, 2016 and is primarily related to foreign currency transaction gains and losses. Interest Income. Interest income was US$3.3 million for the twelve months ended December 31, 2017 compared to US$0.4 million for the twelve months ended December 31, 2016 and is related to our marketable securities portfolio. Interest Expense. Interest expense was US$12.8 million for the twelve months ended December 31, 2017 compared to US$0.7 million for the twelve months ended December 31, 2016 and is related to our 2022 Notes and Revolving Credit Agreement. The increase was primarily due to an additional US$11.1 million of interest expense related to the 2022 Notes. Income Tax Expense. Income tax expense was USUS$1.6 million on a pre-tax loss of USUS$48.6 million, resulting in a negative effective tax rate of 3% for the twelve months ended December 31, 2017, compared to income tax expense of USUS$0.7 million on a pre-tax loss of US$64.9 million and a negative effective tax rate of 1% for the twelve months ended December 31, 2016. The effective tax rate at December 31, 2017 compared to December 31, 2016 increased due to a lower pre-tax net loss. The tax expense for both periods is primarily due to withholding and other income tax expense in profitable jurisdictions.

DexCom Inc © MarketLine

Page 25

DexCom Inc Company Overview

Locations And Subsidaries

LOCATIONS AND SUBSIDARIES Head Office DexCom Inc 6340 Sequence Drive San Diego California San Diego California USA Phone:1 858 2000200 Fax:1 302 6365454 www.dexcom.com

Other Locations and Subsidiaries DexCom Inc

Dxcm Sweden AB Scheelevagen 17 Beta 6 SWE

SweetSpot Diabetes Care, Inc. 919 SW Taylor Street Suite 500 Portland Oregon Portland Oregon USA Phone:1 503 2275272 www.sweetspotdiabetes.com

TypeZero Technologies LLC 919 Second Street South East Charlottesville Virginia Charlottesville Virginia USA Phone:1 434 2848919 www.typezero.com

DexCom Inc © MarketLine

Page 26

DexCom Inc Company Overview

Financial Overview

FINANCIAL OVERVIEW Summarized Statement *Note: Eliminations not included, all figures in Million except per share data. Parameters Income Statements

Currency

2013

2014

2015

2016

2017

Total Revenue Gross Profit

USD

160.00

259.20

402.00

573.30

718.50

USD

100.10

176.30

278.40

378.40

492.10

Operating Income

USD

-28.90

-21.50

-57.10

-63.90

-42.50

Net Income

USD

-29.80

-22.40

-57.60

-65.60

-50.20

Diluted Normalized EPS Balance Sheet

USD

-0.42

-0.30

-0.72

-0.78

0.64

Total Current Assets

USD

93.10

145.90

231.30

280.00

744.70

Total Assets

USD

122.50

184.60

292.00

402.80

904.10

Total Current Liabilities

USD

32.10

40.60

66.90

102.40

138.90

Total Liabilities

USD

38.40

44.40

70.80

119.00

484.70

Total Equity

USD

84.10

140.20

221.20

283.80

419.40

Total Common Shares Outstanding Cash Flow

USD

72.50

77.30

81.70

84.60

87.00

Cash from Operating Activities

USD

2.40

23.60

49.00

56.20

92.00

Cash from Investing Activities

USD

20.90

-16.80

-51.50

-55.90

-144.40

Cash from Financing Activities

USD

11.80

21.80

16.80

8.10

399.10

Net Change in Cash

USD

35.10

28.60

14.30

8.40

347.00

Detailed Statement *Note: Eliminations not included, all figures in Million except per share data. Parameters Income Statements

Currency

2013

2014

2015

2016

2017

Revenue

USD

160.00

259.20

402.00

573.30

718.50

Total Revenue

USD

160.00

259.20

402.00

573.30

718.50

Cost of Revenue, Total

USD

59.90

82.90

123.60

194.90

226.40

Gross Profit

USD

100.10

176.30

278.40

378.40

492.10

Selling/ General/ Admin. Expenses, Total

USD

84.20

128.40

198.00

286.20

349.20

Research & Development

USD

44.80

69.40

137.50

156.10

185.40

Unusual Expense (Income)

USD

0.00

0.00

0.00

0.00

0.00

DexCom Inc © MarketLine

Page 27

DexCom Inc Company Overview

Total Operating Expense

USD

188.90

280.70

459.10

637.20

761.00

Operating Income

USD

-28.90

-21.50

-57.10

-63.90

-42.50

Other, Net

USD

0.00

0.00

0.00

-0.70

3.40

Net Income Before Taxes

USD

-29.80

-22.30

-57.50

-64.90

-48.60

Provision for Income Taxes

USD

0.00

0.10

0.10

0.70

-104.10

Net Income After Taxes

USD

-29.80

-22.40

-57.60

-65.60

55.50

Net Income Before Extra. Items

USD

-29.80

-22.40

-57.60

-65.60

55.50

Total Extraordinary Items

USD

0.00

0.00

0.00

0.00

-105.70

Net Income

USD

-29.80

-22.40

-57.60

-65.60

-50.20

Income Available to Com Excl ExtraOrd

USD

-29.80

-22.40

-57.60

-65.60

55.50

Income Available to Com Incl ExtraOrd

USD

-29.80

-22.40

-57.60

-65.60

-50.20

Dilution Adjustment

USD

0.00

0.00

0.00

0.00

0.00

Diluted Net Income

USD

-29.80

-22.40

-57.60

-65.60

-50.20

Diluted Weighted Average Shares

USD

71.10

75.20

79.80

83.60

86.30

Diluted EPS Excluding ExtraOrd Items

USD

-0.42

-0.30

-0.72

-0.78

0.64

Diluted Normalized EPS

USD

-0.42

-0.30

-0.72

-0.78

0.64

DPS - Common Stock Primary Issue USD Balance Sheet

0.00

0.00

0.00

0.00

0.00

Cash & Equivalents

USD

43.20

71.80

86.10

94.50

441.50

Short Term Investments

USD

11.40

11.80

29.10

29.20

107.10

Cash and Short Term Investments

USD

54.60

83.60

115.20

123.70

548.60

Accounts Receivable - Trade, Net

USD

26.10

42.40

74.10

101.70

134.30

Total Receivables, Net

USD

26.10

42.40

74.10

101.70

134.30

Total Inventory

USD

9.00

16.00

35.20

45.40

45.20

Prepaid Expenses

USD

3.40

3.90

6.80

9.20

16.60

Total Current Assets

USD

93.10

145.90

231.30

280.00

744.70

Property/ Plant/ Equipment, Total Gross

USD

47.30

64.00

92.90

156.60

200.40

Accumulated Depreciation, Total

USD

-26.60

-32.80

-38.20

-47.20

-54.80

Property/ Plant/ Equipment, Total Net

USD

20.70

31.20

54.70

109.40

145.60

Goodwill, Net

USD

3.20

3.20

3.70

11.30

12.10

Intangibles, Net

USD

3.60

2.70

2.20

0.20

0.00

Other Long Term Assets, Total

USD

1.90

1.60

0.10

1.90

1.70

Total Assets

USD

122.50

184.60

292.00

402.80

904.10

Accounts Payable

USD

4.20

9.90

19.00

24.50

46.70

Accrued Expenses

USD

25.00

27.70

44.80

77.00

89.00

DexCom Inc © MarketLine

Page 28

DexCom Inc Company Overview

Notes Payable/ Short Term Debt

USD

0.00

0.00

0.00

0.00

0.00

Current Port. of LT Debt/ Capital Leases

USD

2.20

2.30

2.30

0.00

0.00

Other Current liabilities, Total

USD

0.70

0.70

0.80

0.90

3.20

Total Current Liabilities

USD

32.10

40.60

66.90

102.40

138.90

Long Term Debt

USD

4.60

2.30

0.00

0.00

327.60

Capital Lease Obligations

USD

0.00

0.00

0.00

6.00

6.70

Total Long Term Debt

USD

4.60

2.30

0.00

6.00

334.30

Total Debt

USD

6.80

4.60

2.30

6.00

334.30

Other Liabilities, Total

USD

1.70

1.50

3.90

10.60

11.50

Total Liabilities

USD

38.40

44.40

70.80

119.00

484.70

Redeemable Preferred Stock, Total

USD

0.00

0.00

0.00

0.00

0.00

Common Stock, Total

USD

0.00

0.10

0.10

0.10

0.10

Additional Paid-In Capital

USD

559.50

638.00

776.80

905.70

1,093.70

Retained Earnings (Accumulated Deficit)

USD

-475.40

-497.80

-555.40

-621.00

-671.80

Unrealized Gain (Loss)

USD

0.00

0.00

0.00

0.00

0.00

Other Equity, Total

USD

0.00

-0.10

-0.30

-1.00

-2.60

Total Equity

USD

84.10

140.20

221.20

283.80

419.40

Total Liabilities & Shareholders' Equity

USD

122.50

184.60

292.00

402.80

904.10

Total Common Shares Outstanding Cash Flow

USD

72.50

77.30

81.70

84.60

87.00

Net Income/ Starting Line

USD

-29.80

-22.40

-57.60

-65.60

-50.20

Depreciation/ Depletion

USD

7.00

8.40

10.80

15.00

16.10

Non-Cash Items

USD

28.00

50.40

120.20

113.10

123.50

Changes in Working Capital

USD

-2.80

-12.80

-24.40

-6.30

2.60

Cash from Operating Activities

USD

2.40

23.60

49.00

56.20

92.00

Capital Expenditures

USD

-7.90

-16.20

-33.30

-55.70

-66.00

Other Investing Cash Flow Items, Total

USD

28.80

-0.60

-18.20

-0.20

-78.40

Cash from Investing Activities

USD

20.90

-16.80

-51.50

-55.90

-144.40

Issuance (Retirement) of Stock, Net USD

12.00

24.00

19.10

10.40

10.10

Issuance (Retirement) of Debt, Net

USD

-0.20

-2.20

-2.30

-2.30

389.00

Cash from Financing Activities

USD

11.80

21.80

16.80

8.10

399.10

Foreign Exchange Effects

USD

0.00

0.00

0.00

0.00

0.30

Net Change in Cash

USD

35.10

28.60

14.30

8.40

347.00

Cash Interest Paid

USD

0.50

0.40

0.30

0.10

2.40

Cash Taxes Paid

USD

0.00

0.00

0.10

0.10

1.40

DexCom Inc © MarketLine

Page 29

DexCom Inc Company Overview

Summarized Interim Statement Income Statements

Currency

Dec-2017 (3 Mar-2018 (3 Jun-2018 (3 Sep-2018 (3 Months) Months) Months) Months)

Total Revenue

USD

221.00

184.40

242.50

266.70

Gross Profit

USD

153.50

118.90

153.60

168.60

Operating Income

USD

12.00

-30.70

-4.90

13.90

Net Income

USD

-9.40

-24.20

30.20

46.60

Diluted Normalized EPS

USD

1.11

-0.28

0.34

0.52

Balance Sheet

Currency

Dec-2017

Mar-2018

Jun-2018

Sep-2018

Total Current Assets

USD

744.70

729.30

836.00

914.10

Total Assets

USD

904.10

896.80

1,007.50

1,114.30

Total Current Liabilities

USD

138.90

125.10

170.80

193.90

Total Liabilities

USD

484.70

475.10

525.40

552.10

Total Equity

USD

419.40

421.70

482.10

562.20

Total Common Shares Outstanding

USD

87.00

88.10

87.30

88.80

Cash Flow

Currency

Cash from Operating Activities

USD

92.00

-8.70

32.70

89.50

Cash from Investing Activities

USD

-144.40

-15.40

-175.30

-170.70

Cash from Financing Activities

USD

399.10

4.20

3.40

8.80

Net Change in Cash

USD

347.00

-20.80

-141.00

-73.80

Dec-2017 Mar-2018 (3 Jun-2018 (6 Sep-2018 (9 (12 Months) Months) Months) Months)

Detailed Interim Statement Income Statements

Currency

Revenue

USD

221.00

184.40

242.50

266.70

Total Revenue

USD

221.00

184.40

242.50

266.70

Cost of Revenue, Total

USD

67.50

65.50

88.90

98.10

Gross Profit

USD

153.50

118.90

153.60

168.60

Selling/ General/ Admin. Expenses, Total

USD

92.80

104.80

111.30

104.60

Research & Development

USD

48.70

44.80

47.20

50.10

Total Operating Expense

USD

209.00

215.10

247.40

252.80

Operating Income

USD

12.00

-30.70

-4.90

13.90

Other, Net

USD

-0.10

2.60

-5.60

-1.60

Net Income Before Taxes

USD

8.60

-24.00

29.60

44.80

DexCom Inc © MarketLine

Dec-2017 (3 Mar-2018 (3 Jun-2018 (3 Sep-2018 (3 Months) Months) Months) Months)

Page 30

DexCom Inc Company Overview

Provision for Income Taxes

USD

-87.70

0.20

-0.60

-1.80

Net Income After Taxes

USD

96.30

-24.20

30.20

46.60

Net Income Before Extra. Items

USD

96.30

-24.20

30.20

46.60

Net Income

USD

-9.40

-24.20

30.20

46.60

Income Available to Com Excl ExtraOrd

USD

96.30

-24.20

30.20

46.60

Income Available to Com Incl ExtraOrd

USD

-9.40

-24.20

30.20

46.60

Diluted Net Income

USD

-9.40

-24.20

30.20

46.60

Diluted Weighted Average Shares

USD

86.90

87.30

89.40

90.30

Diluted EPS Excluding ExtraOrd Items USD

1.11

-0.28

0.34

0.52

DPS - Common Stock Primary Issue

USD

0.00

0.00

0.00

0.00

Diluted Normalized EPS

USD

1.11

-0.28

0.34

0.52

Total Extraordinary Items

USD

-105.70

0.00

0.00

0.00

Balance Sheet

Currency

Dec-2017

Mar-2018

Jun-2018

Sep-2018

Cash & Equivalents

USD

441.50

420.40

300.20

367.40

Short Term Investments

USD

107.10

113.50

305.90

301.30

Cash and Short Term Investments

USD

548.60

533.90

606.10

668.70

Accounts Receivable - Trade, Net

USD

134.30

123.90

162.00

169.80

Total Receivables, Net

USD

134.30

123.90

162.00

169.80

Total Inventory

USD

45.20

51.60

46.20

55.20

Prepaid Expenses

USD

16.60

19.90

21.70

20.40

Total Current Assets

USD

744.70

729.30

836.00

914.10

Property/ Plant/ Equipment, Total Gross

USD

200.40

211.30

222.30

241.90

Accumulated Depreciation, Total

USD

-54.80

-58.90

-65.50

-72.30

Property/ Plant/ Equipment, Total Net

USD

145.60

152.40

156.80

169.60

Goodwill, Net

USD

12.10

12.30

11.90

18.40

Other Long Term Assets, Total

USD

1.70

2.80

2.80

12.20

Total Assets

USD

904.10

896.80

1,007.50

1,114.30

Accounts Payable

USD

46.70

38.90

59.90

57.70

Accrued Expenses

USD

89.00

83.30

104.10

132.70

Notes Payable/ Short Term Debt

USD

0.00

0.00

0.00

0.00

Other Current liabilities, Total

USD

3.20

2.90

6.80

3.50

Total Current Liabilities

USD

138.90

125.10

170.80

193.90

Long Term Debt

USD

327.60

331.30

335.00

338.80

Capital Lease Obligations

USD

6.70

7.40

7.30

7.30

Total Long Term Debt

USD

334.30

338.70

342.30

346.10

Total Debt

USD

334.30

338.70

342.30

346.10

DexCom Inc © MarketLine

Page 31

DexCom Inc Company Overview

Other Liabilities, Total

USD

11.50

11.30

12.30

12.10

Total Liabilities

USD

484.70

475.10

525.40

552.10

Redeemable Preferred Stock, Total

USD

0.00

0.00

0.00

0.00

Common Stock, Total

USD

0.10

0.10

0.10

0.10

Additional Paid-In Capital

USD

1,093.70

1,122.50

1,149.10

1,181.60

Retained Earnings (Accumulated Deficit)

USD

-671.80

-696.00

-665.80

-619.20

Other Equity, Total

USD

-2.60

-4.90

-1.30

-0.30

Total Equity

USD

419.40

421.70

482.10

562.20

Total Liabilities & Shareholders' Equity USD

904.10

896.80

1,007.50

1,114.30

87.00

88.10

87.30

88.80

Total Common Shares Outstanding

USD

Cash Flow

Currency

Net Income/ Starting Line

USD

-50.20

-24.20

6.00

52.60

Depreciation/ Depletion

USD

16.10

6.00

12.70

20.50

0.00

0.00

0.00

0.00

Deferred Taxes

Dec-2017 Mar-2018 (3 Jun-2018 (6 Sep-2018 (9 (12 Months) Months) Months) Months)

Non-Cash Items

USD

123.50

20.00

12.30

8.70

Changes in Working Capital

USD

2.60

-10.50

1.70

7.70

Cash from Operating Activities

USD

92.00

-8.70

32.70

89.50

Capital Expenditures

USD

-66.00

-15.30

-25.60

-49.40

Other Investing Cash Flow Items, Total

USD

-78.40

-0.10

-149.70

-121.30

Cash from Investing Activities

USD

-144.40

-15.40

-175.30

-170.70

0.00

0.00

-1.80

-1.80

Financing Cash Flow Items Issuance (Retirement) of Stock, Net

USD

10.10

4.20

5.20

10.60

Issuance (Retirement) of Debt, Net

USD

389.00

0.00

0.00

0.00

Cash from Financing Activities

USD

399.10

4.20

3.40

8.80

Foreign Exchange Effects

USD

0.30

-0.90

-1.80

-1.40

Net Change in Cash

USD

347.00

-20.80

-141.00

-73.80

Cash Taxes Paid

USD

-1.40

0.00

0.00

0.00

Cash Interest Paid

USD

2.40

0.00

0.00

0.00

Capital Market Ratios Key Ratios

February 20,2019

P/E (Price/Earnings) Ratio

0.00

Enterprise Value/Sales

0.00

Enterprise Value/Total Assets

0.00

Dividend Yield

0.00

DexCom Inc © MarketLine

Page 32

DexCom Inc Company Overview

Market Cap

5,766.89

Enterprise Value

0.00

Note: The above ratios are based on the share price as of February 20,2019, they are absolute numbers Annual Ratios Key Ratios

Unit Currency

2013

2014

2015

2016

2017

Sales Growth

%

60.16

62.00

55.09

42.61

25.33

Operating Income Growth

%

0.00

0.00

0.00

0.00

0.00

EBITDA Growth

%

0.00

0.00

0.00

0.00

0.00

Net Income Growth

%

0.00

0.00

0.00

0.00

0.00

EPS Growth

%

0.00

0.00

0.00

0.00

0.00

Working Capital Growth Equity Ratios

%

4.99

72.62

56.13

8.03

241.10

EPS (Earnings per Share)

USD

-0.42

-0.30

-0.72

-0.78

0.64

Dividend per Share

USD

0.00

0.00

0.00

0.00

0.00

Book Value per Share

USD

1.16

1.81

2.71

3.35

4.82

Cash Value per Share Profitability Ratios

USD

0.60

0.93

1.05

1.12

5.07

Gross Margin

%

62.56

68.02

69.25

66.00

68.49

Operating Margin

%

-18.06

-8.29

-14.20

-11.15

-5.92

Net Profit Margin

%

-18.63

-8.64

-14.33

-11.44

-6.99

Profit Markup

%

167.11

212.67

225.24

194.15

217.36

PBT Margin (Profit Before Tax)

%

-18.63

-8.60

-14.30

-11.32

-6.76

Return on Equity

%

-35.43

-15.98

-26.04

-23.11

-11.97

Return on Capital Employed

%

-31.97

-14.93

-25.37

-21.27

-5.55

Return on Assets

%

-26.08

-14.59

-24.17

-18.88

-7.68

Return on Fixed Assets

%

-98.30

-55.56

-94.07

-52.04

-26.66

Return on Working Capital Cost Ratios

%

-47.38

-20.42

-34.73

-35.98

-7.02

Growth Ratios

DexCom Inc © MarketLine

Page 33

DexCom Inc Company Overview

Operating Costs (% of Sales)

%

118.06

108.29

114.20

111.15

105.92

Administration Costs (% of Sales) Liquidity Ratios

%

52.63

49.54

49.25

49.92

48.60

Current Ratio

Absolute

2.90

3.59

3.46

2.73

5.36

Quick Ratio

Absolute

2.62

3.20

2.93

2.29

5.04

Cash Ratio Leverage Ratios

Absolute

1.70

2.06

1.72

1.21

3.95

Debt to Equity Ratio

Absolute

0.08

0.03

0.01

0.02

0.80

Net Debt to Equity

Absolute

-0.43

-0.48

-0.38

-0.31

-0.26

Debt to Capital Ratio Efficiency Ratios

Absolute

0.07

0.03

0.01

0.02

0.44

Asset Turnover

Absolute

1.40

1.69

1.69

1.65

1.10

Fixed Asset Turnover

Absolute

8.08

9.99

9.36

6.99

5.64

Inventory Turnover

Absolute

7.30

6.63

4.83

4.84

5.00

Current Asset Turnover

Absolute

1.87

2.17

2.13

2.24

1.40

Capital Employed Turnover

Absolute

1.77

1.80

1.79

1.91

0.94

Working Capital Turnover

Absolute

2.62

2.46

2.45

3.23

1.19

Revenue per Employee

USD

0.00

0.00

0.00

0.00

313,755.46

Net Income per Employee

USD

0.00

0.00

0.00

0.00

-21,921.40

Capex to Sales

%

4.94

6.25

8.28

9.72

9.19

R&D to Sales

%

28.00

26.77

34.20

27.23

25.80

Interim Ratios Key Ratios

Currency

EPS (Earnings per Share)

USD

1.11

-0.28

0.34

0.52 Equity Ratios

Book Value per Share USD

4.82

4.79

5.52

6.33 Equity Ratios

Current Ratio

5.36

5.83

4.90

4.71 Liquidity Ratios

DexCom Inc © MarketLine

Absolute

December March June September Ratio Type 01,2017 01,2018 01,2018 01,2018

Page 34

A Progressive Digital Media business

John Carpenter House, John Carpenter Street, London, United Kingdom, EC4Y 0AN T: +44 (0) 203 377 3042 | F: +44 (0) 870 134 4371 | E: [email protected] | W: www.marketline.com